Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 In vitro refolded human leukocyte antigen (HLA)–A2:peptide complexes activate TZR 2D1 In vitro refolded human leukocyte antigen (HLA)–A2:peptide.

Published byAdi Lesmana Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 In vitro refolded human leukocyte antigen (HLA)–A2:peptide complexes activate TZR 2D1 In vitro refolded human leukocyte antigen (HLA)–A2:peptide."— Presentation transcript:

1 Figure 2 In vitro refolded human leukocyte antigen (HLA)–A2:peptide complexes activate TZR 2D1
In vitro refolded human leukocyte antigen (HLA)–A2:peptide complexes activate TZR 2D1 (A) Sodium dodecyl sulfate polyacrylamide gel electrophoresis of HLA-A*02:01 (HLA-A2) refolded from recombinant heavy chain and β2m in the presence of either the octameric glycerolphosphatidylcholine phosphodiesterase 1 (GPCPD1) (15-22) or the nonameric M-GPCPD1(15-22) under reducing and nonreducing conditions. Lanes 1 and 6, protein standard. Molecular masses are given in kDa at the left; lane 2, HLA-A2, β2m, and M-GPCPD1(15-22) under reducing conditions; lane 3, HLA-A2, β2m, and GPCPD1(15-22) under reducing conditions; lane 4, HLA-A2, β2m, and M-GPCPD1(15-22) under nonreducing conditions; lane 5, HLA-A2, β2m, and GPCPD1(15-22) under nonreducing conditions. (B) Activation of 58α−β− T hybridoma cells expressing TCR 2D1, human CD8αβ molecules, and sGFP under the control of nuclear factor of activated T cells (58-2D1-CD8-sGFP) cells by in vitro refolded trimeric HLA-A2:β2m:peptide complexes as measured by fluorescence microscopy. Left panel: 58-2D1-CD8-sGFP cells were incubated with refolded and biotinylated HLA-A2, β2m, and GPCPD1(15-22). Right panel: As left panel, but with M-GPCPD1(15-22). Scale bars: 100 μm. (C) IL-2 concentration measured in the supernatant from the experiments shown in (B). Error bars represent SD of the mean. Geraldine Rühl et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e241 © 2016 American Academy of Neurology

Download ppt "Figure 2 In vitro refolded human leukocyte antigen (HLA)–A2:peptide complexes activate TZR 2D1 In vitro refolded human leukocyte antigen (HLA)–A2:peptide."

Similar presentations

Suppressive Effects of Cyclosporin A and FK-506 on Superoxide Generation in Human Polymorphonuclear Leukocytes Primed by Tumor Necrosis Factor α  Yasushi.

Suppressive Effects of Cyclosporin A and FK-506 on Superoxide Generation in Human Polymorphonuclear Leukocytes Primed by Tumor Necrosis Factor α  Yasushi.
Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)

Figure 4 Number of subjects with positive DTH response to recall antigens before and at the end of treatmentA positive delayed-type hypersensitivity (DTH)
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 2 GlyR antibody binding

Figure 2 GlyR antibody binding
Characterization of assembly of recombinant type IV collagen α3, α4, and α5 chains in transfected cell strains  Takehiro Kobayashi, Makoto Uchiyama  Kidney.

Characterization of assembly of recombinant type IV collagen α3, α4, and α5 chains in transfected cell strains  Takehiro Kobayashi, Makoto Uchiyama  Kidney.
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Peptidylarginine Deiminase Isoforms 1–3 Are Expressed in the Epidermis and Involved in the Deimination of K1 and Filaggrin  Rachida Nachat, Marie-Claire.

Peptidylarginine Deiminase Isoforms 1–3 Are Expressed in the Epidermis and Involved in the Deimination of K1 and Filaggrin  Rachida Nachat, Marie-Claire.
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.

Figure 2 Immunopathologic analysis of all 3 Rasmussen encephalitis cases Immunopathologic analysis of all 3 Rasmussen encephalitis cases (A) Perivascular.
Figure 2 M1 and M23 AQP4 isoforms compared by freeze-fracture electron microscopic and Western blot analyses M1 and M23 AQP4 isoforms compared by freeze-fracture.

Figure 2 M1 and M23 AQP4 isoforms compared by freeze-fracture electron microscopic and Western blot analyses M1 and M23 AQP4 isoforms compared by freeze-fracture.
Figure 1 Reactivity of the patients' antibodies with rat brain and HEK cell-based assays Rat hippocampal dentate gyrus neuropils were stained with patient.

Figure 1 Reactivity of the patients' antibodies with rat brain and HEK cell-based assays Rat hippocampal dentate gyrus neuropils were stained with patient.
Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.

Figure 2 Brain biopsy Brain biopsy (A) Double staining with anti-aquaporin-4 (AQP4) antibody (dark green) and Luxol fast blue (blue) is shown. Loss of.
Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.

Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.
Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.

Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.
Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.
Figure 1 T-cell receptor 2D1 recognizes human leukocyte antigen (HLA)–A2–restricted octameric and nonameric synthetic peptides T-cell receptor 2D1 recognizes.

Figure 1 T-cell receptor 2D1 recognizes human leukocyte antigen (HLA)–A2–restricted octameric and nonameric synthetic peptides T-cell receptor 2D1 recognizes.
Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Similar presentations

Ads by Google